The Food and Drug Administration’s Pharmacy Compounding Advisory Committee recently recommended that six previously restricted peptides be made available for pharmacy compounding. The approved peptides include BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, which are promoted for conditions ranging from ulcerative colitis to neurological disorders. Only emideltide was rejected in a 7-6 vote. Each affirmative vote was narrowly decided, with margins such as 8-6 and 7-4, prompting scrutiny over the consistency of the evaluations.
Committee Composition and Ethics Concerns
The FDA added eight new members to the committee shortly before the meeting. Reports indicate that six of these members had direct ties to the peptide industry, either as sellers or affiliates of clinics, pharmacies, or companies operating in the peptide market. For example, Dr. Gabriel Alizaidy, the scientific director of Maximus Health, a telehealth company offering peptide-related services, was among the new appointees. The FDA has previously warned Maximus over misleading claims involving compounded GLP-1 products. Another appointee, Tennessee state Sen. Bobby Harshbarger, is a pharmacist in his family’s compounding business. His mother, Rep. Diana Harshbarger (R-TN), had written to the FDA regarding peptide regulations.
Industry Growth and Safety Concerns
Peptides have gained popularity in the wellness and beauty industries, with U.S. searches for peptide-related terms reaching 10.1 million per month in January 2024, a fivefold increase since 2020. Academics at Northeastern University have expressed concerns about the rapid adoption of peptides outpacing safety and efficacy data. The FDA’s decision comes amid growing interest in peptides for anti-aging, weight loss, and other applications, including the widespread use of GLP-1 drugs like Ozempic and Mounjaro.
Regulatory and Public Health Implications
The FDA’s decision could expand access to peptides, which are currently marketed for a variety of conditions. However, critics argue that the close vote margins and the committee’s industry ties raise questions about the objectivity of the approval process. The FDA has not yet issued a final ruling on the recommendations, and further review is expected.